Subcutaneous Self Injection Markets to 2026

$3,850.00

Several pharma and biotech companies are embracing the combination product concept for subcutaneous injectables and using it to differentiate their drug offerings, while others are opting for a minimalist approach. Interferons for treating Multiple Sclerosis are primarily marketed in prefilled syringes, while human growth hormone indicated for hormone deficiency in children is supplied almost exclusively in reusable, custom-designed variable dose pen injectors. Even within a particular therapeutic drug class, strategic variations are evident.

Category:

Description

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application. As these combination products have proliferated, so too have product strategies.